Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1159/000218081. Epub 2009 May 12.
Affiliations
- PMID: 19439966
- DOI: 10.1159/000218081
Randomized Controlled Trial
Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study
Yvonne Freund-Levi et al. Dement Geriatr Cogn Disord. 2009.
Abstract
Background: omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer's disease (AD).
Objective: To study the effects of dietary omega-3 FA supplementation on inflammatory markers in cerebrospinal fluid (CSF) and plasma from patients with mild to moderate AD.
Methods: Thirty-five patients (70.3 +/- 8.2 years) were randomized to a daily intake of 2.3 g omega-3 FAs or placebo for 6 months. The inflammatory markers interleukin (IL)-6, tumour necrosis factor-alpha and soluble interleukin-1 receptor type II (sIL-1RII) were analysed in CSF and plasma at baseline and at 6 months. The AD markers tau-protein, hyperphosphorylated tau-protein and beta-amyloid (Abeta(1-42)) were assessed in CSF. High-sensitivity C-reactive protein was assessed in plasma. A possible relation to the APOE genotype was investigated.
Results: There was no significant treatment effect of omega-3 FAs on inflammatory and AD biomarkers in CSF or on inflammatory markers in plasma, nor was there any relation with APOE. A significant correlation was observed at baseline between sIL-1RII and Abeta(1-42) levels in CSF.
Conclusions: Treatment of AD patients with omega-3 FAs for 6 months did not influence inflammatory or biomarkers in CSF or plasma. The correlation between sIL-1RII and Abeta(1-42) may reflect the reciprocal interactions between IL-1 and Abeta peptides.
Similar articles
- Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N Jr, Palmblad J. Freund Levi Y, et al. J Intern Med. 2014 Apr;275(4):428-36. doi: 10.1111/joim.12166. Epub 2014 Jan 11. J Intern Med. 2014. PMID: 24410954 Clinical Trial. - Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study.
Irving GF, Freund-Levi Y, Eriksdotter-Jönhagen M, Basun H, Brismar K, Hjorth E, Palmblad J, Vessby B, Vedin I, Wahlund LO, Cederholm T. Irving GF, et al. J Am Geriatr Soc. 2009 Jan;57(1):11-7. doi: 10.1111/j.1532-5415.2008.02055.x. Epub 2008 Nov 20. J Am Geriatr Soc. 2009. PMID: 19054188 Clinical Trial. - Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Freund-Levi Y, et al. Arch Neurol. 2006 Oct;63(10):1402-8. doi: 10.1001/archneur.63.10.1402. Arch Neurol. 2006. PMID: 17030655 Clinical Trial. - Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T, Shoji M. Kawarabayashi T, et al. Curr Opin Psychiatry. 2008 May;21(3):260-7. doi: 10.1097/YCO.0b013e3282fc989f. Curr Opin Psychiatry. 2008. PMID: 18382225 Review. - Amyloid beta and APP as biomarkers for Alzheimer's disease.
Zetterberg H, Blennow K, Hanse E. Zetterberg H, et al. Exp Gerontol. 2010 Jan;45(1):23-9. doi: 10.1016/j.exger.2009.08.002. Epub 2009 Aug 19. Exp Gerontol. 2010. PMID: 19698775 Review.
Cited by
- Ketogenic Diet: An Effective Treatment Approach for Neurodegenerative Diseases.
Tao Y, Leng SX, Zhang H. Tao Y, et al. Curr Neuropharmacol. 2022 Nov 15;20(12):2303-2319. doi: 10.2174/1570159X20666220830102628. Curr Neuropharmacol. 2022. PMID: 36043794 Free PMC article. Review. - Omega-3 fatty acids for the treatment of dementia.
Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Burckhardt M, et al. Cochrane Database Syst Rev. 2016 Apr 11;4(4):CD009002. doi: 10.1002/14651858.CD009002.pub3. Cochrane Database Syst Rev. 2016. PMID: 27063583 Free PMC article. Review. - Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.
Dacks PA, Shineman DW, Fillit HM. Dacks PA, et al. J Nutr Health Aging. 2013 Mar;17(3):240-51. doi: 10.1007/s12603-012-0431-3. J Nutr Health Aging. 2013. PMID: 23459977 - Epidemiology of Alzheimer disease.
Reitz C, Brayne C, Mayeux R. Reitz C, et al. Nat Rev Neurol. 2011 Mar;7(3):137-52. doi: 10.1038/nrneurol.2011.2. Epub 2011 Feb 8. Nat Rev Neurol. 2011. PMID: 21304480 Free PMC article. Review. - Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype.
Barberger-Gateau P, Samieri C, Féart C, Plourde M. Barberger-Gateau P, et al. Curr Alzheimer Res. 2011 Aug;8(5):479-91. doi: 10.2174/156720511796391926. Curr Alzheimer Res. 2011. PMID: 21605054 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous